These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): A retrospective analysis of 235 patients from a nationwide survey in Japan. Harabuchi Y; Kishibe K; Tateyama K; Morita Y; Yoshida N; Kunimoto Y; Matsui T; Sakaguchi H; Okada M; Watanabe T; Inagaki A; Kobayashi S; Iino Y; Murakami S; Takahashi H; Tono T Mod Rheumatol; 2017 Jan; 27(1):87-94. PubMed ID: 27166750 [TBL] [Abstract][Full Text] [Related]
3. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis. Csernok E; Lamprecht P; Gross WL Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659 [TBL] [Abstract][Full Text] [Related]
4. Pathogenesis and diagnosis of otitis media with ANCA-associated vasculitis. Yoshida N; Iino Y Allergol Int; 2014 Dec; 63(4):523-32. PubMed ID: 25339433 [TBL] [Abstract][Full Text] [Related]
10. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904 [TBL] [Abstract][Full Text] [Related]
11. The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis. Okada M; Suemori K; Takagi D; Teraoka M; Yamada H; Ishizaki J; Matsumoto T; Hasegawa H; Hato N Auris Nasus Larynx; 2019 Feb; 46(1):38-42. PubMed ID: 29885746 [TBL] [Abstract][Full Text] [Related]
12. Increased membrane expression of proteinase 3 during neutrophil adhesion in the presence of anti proteinase 3 antibodies. Brachemi S; Mambole A; Fakhouri F; Mouthon L; Guillevin L; Lesavre P; Halbwachs-Mecarelli L J Am Soc Nephrol; 2007 Aug; 18(8):2330-9. PubMed ID: 17634439 [TBL] [Abstract][Full Text] [Related]
14. IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients. Harper L; Radford D; Plant T; Drayson M; Adu D; Savage CO Arthritis Rheum; 2001 Apr; 44(4):921-30. PubMed ID: 11315931 [TBL] [Abstract][Full Text] [Related]
15. Long-term treatment results and the immunoglobulin G subclass distribution patterns of proteinase-3-antineutrophil cytoplasm antibody (ANCA) and myeloperoxidase-ANCA in ANCA-associated vasculitis. Almroth G; Berlin G; Andersson B; Hahn-Zoric M Scand J Urol Nephrol; 2009; 43(2):160-70. PubMed ID: 18979374 [TBL] [Abstract][Full Text] [Related]